Abstract:Anti-TNF antibody has been an effective therapeutic strategy for the diseases related to aberrant production of TNF-alpha, such as rheumatoid arthritis (RA) and Crohn's disease. The limitations of large molecule inhibitors in the therapy of these diseases prompted the search for other potent novel TNF-alpha antagonists. Antagonistic peptides, derived directly or designed rationally from complementarity-determining regions (CDRs) of neutralizing antibodies against TNF-alpha, have been demonstrated for their ability of inhibiting TNF-alpha. However, their activity is very low. In this study, to increase the affinity and bioactivity, human antibody variable region was used as scaffold to display antagonistic peptides, which were designed on the interaction between TNF-alpha and its neutralizing monoclonal antibody (mAb Z12). Based on the previously designed domain antibody (framework V(H)5), framework V(kappa)1 was used as light chain scaffold. On the basis of computer-guided molecular design method, a novel human scFv fragment (named as TSA1) was designed. Theoretical analysis showed that TSA1 could bind to TNF-alpha with more hydrogen bonds and lower binding free energy than the designed domain antibody. The biological experiments demonstrated that TSA1 could directly bind with TNF-alpha, competitively inhibit the binding of mAb Z12 to TNF-alpha and block the binding of TNF-alpha to TNFR I and TNFR II. TSA1 could also inhibit TNF-induced cytotoxicity on L929 cells and TNF-mediated NF-kappaB activation on HEK-293T cells. The bioactivity of TSA1 was significantly increased over the domain antibody. This study indicated that the framework of antibody variable region could serve as an ideal scaffold for displaying the peptides and provides a novel strategy to design TNF-alpha inhibitors with the ability to block the deleterious biological effects of TNF-alpha.

A Novel Human Scfv Fragment Against Tnf-Alpha from De Novo Design Method

A novel anti-TNF scFv constructed with human antibody frameworks and antagonistic peptides

A Novel Domain Antibody Rationally Designed Against TNF-α Using Variable Region of Human Heavy Chain Antibody As Scaffolds to Display Antagonistic Peptides

Novel human single chain antibody design based on the functional epitope of TNF

A Novel TNFα Antagonizing Peptide-Fc Fusion Protein Designed Based on CDRs of TNFα Neutralizing Monoclonal Antibody

De Novo Design TNF-α Antagonistic Peptide Based on the Complex Structure of TNF-α with Its Neutralizing Monoclonal Antibody Z12

Humanization of an Anti-Human Tnf-Alpha Antibody by Variable Region Resurfacing with the Aid of Molecular Modeling

Overexpression, Effective Renaturation, and Bioactivity of Novel Single-Chain Antibodies Against TNF-α

Overexpression, Effective Renaturation, And Bioactivity Of Novel Single-Chain Antibodies Against Tnf-Alpha

A Novel Bivalent Single‐chain Variable Fragment (scfv) Inhibits the Action of Tumour Necrosis Factor Α

Optimization and Modification of Anti-Rhtnf-α Single Chain Variable Fragment Antibody: Effective in Vitro Affinity Maturation and Functional Expression of Chimeric Fab.

Reconstruction and Analysis of A Human Small Molecular Antibody to Tumor Necrosis Factor Alpha

Retraction Note To: Structure-based Development and Optimization of Therapy Antibody Drugs Against TNFα

Designing and constructing a phage display synthesized single domain antibodies library based on camel VHHs frame for screening and identifying humanized TNF-α-specific nanobody

Characterization of a novel anti-human TNF-α murine monoclonal antibody with high binding affinity and neutralizing activity

Targeting TNF-α with a tetravalent mini-antibody TNF-TeAb

The Protective Antibodies Induced by a Novel Epitope of Human TNF-α Could Suppress the Development of Collagen-Induced Arthritis

[Development of an Anti-Rtnf-alpha Chimeric Antibody].

Covalently dimerized Camelidae antihuman TNFa single-domain antibodies expressed in yeast Pichia pastoris show superior neutralizing activity

One-Step On-Column Purification And Refolding Of A Single-Chain Variable Fragment (Scfv) Antibody Against Tumour Necrosis Factor Alpha

Rational Design of TNFα Binding Proteins Based on the De Novo Designed Protein DS119